(Q38827586)

6 September 2017

1 reference

title

Emerging and future therapies for nonalcoholic steatohepatitis in adults (English)

1 reference

6 September 2017

0 references

Gesthimani Mintziori

1

1 reference

6 September 2017

Stergios A Polyzos

series ordinal

2

1 reference

6 September 2017

language of work or name

English

0 references

publication date

26 August 2016

1 reference

Expert Opinion on Pharmacotherapy

6 September 2017

published in

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

14

1 reference

6 September 2017

page(s)

1937-1946

1 reference

Epidemiology and natural history of non-alcoholic fatty liver disease.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Non-alcoholic fatty liver disease and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nonalcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

NASH, from diagnosis to treatment: Where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nonalcoholic fatty liver disease and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Intestinal microbiota in liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The effect of a probiotic on hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-li

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Fatty acid bile acid conjugate inhibits hepatic stearoyl coenzyme A desaturase and is non-atherogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Adipokines in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Leptin in nonalcoholic fatty liver disease: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Nonalcoholic fatty future disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Helicobacter pylori infection in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14656566.2016.1225727

10.1080/14656566.2016.1225727

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference